Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Talimogene laherparepvec|
Imlygic (talimogene laherparepvec) is a GM-CSF expressing herpes simplex type-1 virus (HSV-1) that selectively infects and lyses tumor cells, and potentially induces a cytotoxic immune response against tumor cells (PMID: 25777572). Imlygic (talimogene laherparepvec) is FDA approved for use in patients with recurrent melanoma (FDA.gov).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Talimogene laherparepvec||Imlygic||OncoVEX GM-CSF||Imlygic (talimogene laherparepvec) is a GM-CSF expressing herpes simplex type-1 virus (HSV-1) that selectively infects and lyses tumor cells, and potentially induces a cytotoxic immune response against tumor cells (PMID: 25777572). Imlygic (talimogene laherparepvec) is FDA approved for use in patients with recurrent melanoma (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||melanoma||not applicable||Talimogene laherparepvec||FDA approved||Actionable||In a Phase III trial that supported FDA approval, Imlygic (talimogene laherparepvec) treatment resulted in significantly improved durable response rate (16.3% vs 2.1%, OR=8.9, p<0.001), overall response rate (26.4% vs 5.7%), and median overall survival (23.3 vs 18.9 months, HR=0.79, p=0.051) compared to GM-CSF in patients with melanoma (PMID: 26014293; NCT00769704).||26014293 detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02509507||Phase I||Pembrolizumab + Talimogene laherparepvec Talimogene laherparepvec||Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab||Recruiting|
|NCT02923778||Phase II||Talimogene laherparepvec||Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery||Recruiting|
|NCT02453191||Phase Ib/II||Talimogene laherparepvec||TVEC and Preop Radiation for Sarcoma||Active, not recruiting|
|NCT01740297||Phase Ib/II||Ipilimumab Talimogene laherparepvec||Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma||Active, not recruiting|
|NCT02263508||Phase Ib/II||Pembrolizumab Talimogene laherparepvec||MK-3475 With or Without Talimogene Laherparepvec in Unresected Melanoma||Active, not recruiting|
|NCT02658812||Phase II||Talimogene laherparepvec||Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery||Active, not recruiting|
|NCT02819843||Phase II||Talimogene laherparepvec||A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors||Recruiting|
|NCT03663712||Phase I||Talimogene laherparepvec||Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies (TEMPO)||Recruiting|
|NCT02756845||Phase I||Talimogene laherparepvec||Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors||Recruiting|
|NCT03086642||Phase I||Talimogene laherparepvec||Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer||Recruiting|